Genfit S.A. ADR (GNFT)

$4.85 +0.12 (2.54%)
Market Cap 242.62M
Revenue (ttm) 76.76M
Net Income (ttm) 1.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 2.12%
Debt to Equity Ratio 0.14
Volume 56,900
Avg Vol 11,412
Day's Range N/A - N/A
Shares Out 50.03M
Stochastic %K 93%
Beta 1.09
Analysts Strong Sell
Price Target $7.50

Company Profile

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 20 16 40 00
Fax: 33 2 20 16 40 01
Address:
Parc EurasantE, 885, avenue EugEne AvinEe, Loos, France
judgeyoung2
judgeyoung2 Dec. 3 at 4:29 PM
$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.
0 · Reply
TwongStocks
TwongStocks Nov. 20 at 5:03 PM
$GNFT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market https://ir.genfit.com/news-releases/news-release-details/genfit-announces-effectiveness-voluntary-delisting-american
0 · Reply
Doozio
Doozio Nov. 20 at 2:36 AM
$GNFT 🐒🍌🧠⏰♾️
0 · Reply
BLD33
BLD33 Nov. 11 at 3:24 PM
$GNFT 9 days of covering !!!
0 · Reply
twincam
twincam Nov. 10 at 11:29 PM
$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.
0 · Reply
Noobnr1
Noobnr1 Nov. 10 at 5:47 PM
$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:56 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-enters-research-collaboration-everzom-advance-exosome
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:55 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-presents-promising-new-preclinical-data-ntzg1090n
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 3 at 1:27 PM
$GNFT Current Stock Price: $3.85 No options data available.
0 · Reply
Rickycello
Rickycello Oct. 28 at 9:45 PM
$GNFT !!! Mark the day!!! "...announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025."
0 · Reply
Latest News on GNFT
No data available.
judgeyoung2
judgeyoung2 Dec. 3 at 4:29 PM
$GNFT GNS561 in CCA – Data readout from the ongoing Phase 1b clinical trial are expected by the end of 2025.
0 · Reply
TwongStocks
TwongStocks Nov. 20 at 5:03 PM
$GNFT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market https://ir.genfit.com/news-releases/news-release-details/genfit-announces-effectiveness-voluntary-delisting-american
0 · Reply
Doozio
Doozio Nov. 20 at 2:36 AM
$GNFT 🐒🍌🧠⏰♾️
0 · Reply
BLD33
BLD33 Nov. 11 at 3:24 PM
$GNFT 9 days of covering !!!
0 · Reply
twincam
twincam Nov. 10 at 11:29 PM
$GPCR $NVO $NVO’s next M&A wave likely targets small-cap metabolic names it can absorb fast 👀 🧩 $GPCR — oral GLP-1, sweet spot ~$2-4B 💊 $IVA — late-stage MASH, ~$1B w/ CVR 🧬 $GNFT — liver bolt-on <$0.5B 🐍 $ZEAL — combo peptide giant $7-14B (too rich?) Smart money’s betting Novo reloads with bite-sized deals, not another bidding war.
0 · Reply
Noobnr1
Noobnr1 Nov. 10 at 5:47 PM
$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:56 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-enters-research-collaboration-everzom-advance-exosome
0 · Reply
Rickycello
Rickycello Nov. 10 at 6:55 AM
$GNFT https://ir.genfit.com/news-releases/news-release-details/genfit-presents-promising-new-preclinical-data-ntzg1090n
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 3 at 1:27 PM
$GNFT Current Stock Price: $3.85 No options data available.
0 · Reply
Rickycello
Rickycello Oct. 28 at 9:45 PM
$GNFT !!! Mark the day!!! "...announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025."
0 · Reply
abbk
abbk Oct. 24 at 4:42 PM
$GNFT not trading? no movement
0 · Reply
Amb8675309
Amb8675309 Oct. 9 at 5:36 PM
$GNFT what’s with the “new orders not being accepted at this time” message
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 3:49 PM
$GNFT Brilliant piece that captures GNFT's situation perfectly. So if you want to update your understanding of GNFT or get to know GNFT better, this is essential reading. https://beyondspx.com/quote/GNFT/analysis/genfit-s-strategic-reorientation-unlocking-value-in-liver-diseases-and-diagnostics-nasdaq-gnft
0 · Reply
DARKP00L
DARKP00L Sep. 23 at 8:35 PM
$GNFT 13:58 on Sep. 23 2025 GENFIT shares are trading lower after the company reported a year-over-year decrease in H1 financial results. #tradeideas
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 23 at 12:39 PM
$GNFT (-6.3% pre) Genfit S.A. GAAP EPS of -€0.20, revenue of €35.67M https://ooc.bz/l/78090
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 22 at 12:33 PM
Top Earnings Mon 9/22 Aft: $FLY $GNFT . Top Earnings Tu 9/23 Pre: $AZO
0 · Reply
Maryanne_trades
Maryanne_trades Sep. 22 at 2:51 AM
$GNFT $AZO $MU $AYTU $UEC $THO $SFIX $KBH $BB $ACN $KMX $COST $LPTH $IVA
0 · Reply
TomOfWallStreet
TomOfWallStreet Sep. 19 at 6:07 PM
$GNFT any ideas how earnings might play out?
0 · Reply
JarvisFlow
JarvisFlow Aug. 19 at 12:00 PM
HC Wainwright & Co. has updated their rating for Genfit ( $GNFT ) to Buy with a price target of 9.
0 · Reply
maxstk
maxstk Aug. 4 at 7:55 AM
$TNXP – Best high-risk/high-reward play of 2025. $GNFT – Your next strategic move. - Already has 1 approved & commercialized product - Strong pipeline - Critical data readout expected this month
0 · Reply